H+H International A/S
17.3.2021 08:27:39 CET | Globenewswire | Press release
On 4 March 2021, H+H International A/S (hereinafter referred to as "H+H" or "the Company") initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the "Safe Harbour Regulation").
The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2021. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 100 million, and no more than 1,728,136 shares, corresponding to approximately 9.6 percent of the share capital of the Company.
The following transactions were executed under the share buy-back programme from 10 March 2021 to 16 March 2021:
| No. of shares | Average price (DKK) | Total value (DKK) | |
| Accumulated, last announcement | 18,500 | 2,759,915.00 | |
| 10 March 2021 | 4,400 | 153.28 | 674,432.00 |
| 11 March 2021 | 4,300 | 156.43 | 672,649.00 |
| 12 March 2021 | 4,300 | 156.42 | 672,606.00 |
| 15 March 2021 | 5,000 | 152.74 | 763,700.00 |
| 16 March 2021 | 4,000 | 150.90 | 603,600.00 |
| Total | 22,000 | 3,386,987.00 | |
| Accumulated under the programme | 40,500 | 6,146,902.00 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions, H+H holds 110,700 shares as treasury shares, corresponding to 0.62 percent of the Company’s total share capital.
For further information please contact:
Andreas Holkjær
Investor Relations and Treasury Manager
+45 24 48 03 67
aho@HplusH.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
